Merck to Participate in the TD Cowen 46th Annual Health Care Conference

RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the TD Cowen 46th Annual Health Care Conference.

Business Wire • 17 hours ago

Merck is establishing a separate cancer unit. The reorganization of its pharmaceutical business is aimed at bolstering product launches ahead of a key patent loss.

The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss.

WSJ • Feb 23, 2026

Merck to create separate cancer business to offset Keytruda patent loss, WSJ reports

Drugmaker Merck is separating its human-health business into two divisions to offset pressures related to the patent loss of its top-selling drug Keytruda, the Wall Street Journal reported on Monday.

Reuters • Feb 23, 2026

US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost

U.S. Food and Drug Administration Commissioner Marty Makary on Monday defended his agency's position and record on mRNA vaccines, days after it changed course and agreed to review a Moderna flu vaccine.

Reuters • Feb 23, 2026

Merck creates separate oncology arm ahead of Keytruda patent loss

Merck said on Monday that it will split its human-health operations into two separate divisions, a move designed to sharpen focus across its portfolio and ensure smoother launches of new medicines. The move comes as the drugmaker seeks to prepare for mounting sales pressure later this decade, driven by the looming loss of exclusivity for its top-selling cancer drug Keytruda, which will also expose it to lower-cost copycat competition.

Invezz • Feb 23, 2026

Merck reportedly ready to the splits as Keytruda patent cliff looms. Market shrugs

Investors gave a collective meh to news that Merck & Co Inc (NYSE:MRK, XETRA:6MK) is reportedly restructuring its human-health division, with shares marking time in premarket trading despite a reorganisation that signals the US drugmaker is bracing for the biggest revenue hit in its recent history. The Wall Street Journal reported on Monday that Merck plans to separate its human-health operations into two distinct divisions.

Proactive Investors • Feb 23, 2026

Merck Evolves Human Health Operating Structure to Support Portfolio Execution

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Evolves Human Health Operating Structure to Support Portfolio Execution.

Business Wire • Feb 23, 2026

Merck Creates Separate Cancer Business. The Stock Is Rising Ahead of Patent Cliff.

The drug maker is splitting up its Human Health business before patent protection on its blockbuster treatment Keytruda expires in two years.

Barrons • Feb 23, 2026

Harbor Large Cap Value Fund Q4 2025 Portfolio Review

During the fourth quarter, the Harbor Large Cap Value Fund returned 1.26%, underperforming its benchmark, the Russell 1000® Value Index, which returned 3.81%, and underperforming the 2.66% return of the S&P 500 Index. The top five contributors to relative performance during the fourth quarter were: Parker Hannifin, Capital One Financial, Amgen, Merck, and Danaher. The bottom five detractors from relative performance were: Lennar, Uber, Sony, Microsoft, and Teledyne Technologies.

Seeking Alpha • Feb 23, 2026

Could Merck Stock Quietly Help Turn Steady Dividends Into a Millionaire Retirement?

Merck is one of the world's largest drug companies. Although it isn't a player in the GLP-1 space, it has a well-supported dividend and a proven track record of dividend growth.

The Motley Fool • Feb 22, 2026